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Background: Patients with coronary artery disease (CAD) are at risk of accelerated cognitive decline, particularly
those with major depression. Mechanisms for cognitive deficits associated with CAD, and the effects of depression,
remain poorly understood. However, CAD is associated with inflammatory processes that have been linked to
neurodegeneration, may contribute to cognitive decline, and are elevated in depression. Platelet-activating factors
(PAFs) are emerging as key lipid mediators that may be central to those processes and highly relevant to cognitive
decline in CAD.
Methods: This cross-sectional study investigated relationships between various PAFs and cognitive performance in
24 patients with CAD (age, 60.3 ± 9.4; 70.8% male). Analyses were repeated in a subgroup of 15 patients with CAD
with major depression (DSM-IV). Cognitive performance was assessed using a standardized battery and summary z
scores were calculated based on age, sex, and education norms. Global cognitive performance was the average of
domain-specific z scores. Plasma PAF analyses were performed using electrospray ionization mass spectrometry
(precursor ion scan).
Results: A greater abundance of PAF PC(O-18:0/2:0) was associated with poorer global cognitive performance in
patients with CAD (r = −0.45, P = 0.03). In the major depressed subgroup, PAF PC(O-18:0/2:0) (r = −0.59, P = 0.02) as
well as PC(O-16:0/2:0) (r = −0.52, P = 0.04), and lyso-PAF PC(O-16:0/0:0) (r = −0.53, P = 0.04) were associated with
poorer global cognitive performance. A greater abundance of PAF PC(O-19:5/2:0) was associated with better global
cognitive performance (r = 0.55, P = 0.03), suggesting a possible compensatory species.
Conclusions: This study suggests that certain PAFs might be associated with global cognitive performance in
patients with CAD, with stronger relationships observed in those with major depression. Confirmation of these
preliminary findings is warranted.
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Cognitive deficits are prevalent in patients with coronary
artery disease (CAD) [1-4] and, accordingly, patients with
CAD are at risk of accelerative cognitive decline and tran-
sition to dementia [5]. Major depression significantly amp-
lifies the rate of cognitive decline in those with CAD [6,7],
as well as worsening functional outcomes and increasing
the risk of mortality [8,9]. The prevention of cognitive de-
cline in patients with CAD may rely not only on adequate
treatment of depressive symptoms, but also on a targeted
inhibition of the mechanisms leading to cognitive decline
in those with depression. Unfortunately, response rates to
antidepressant therapies are modest in patients with CAD
[10,11] and there are no consistently effective treatments
to prevent cognitive decline [12]. Furthermore, the mecha-
nisms of cognitive decline in patients with CAD, and the
contributions of depression, are poorly understood.
Recent reviews have implicated aberrant lipid metabol-
ism, inflammatory activity, and oxidative stress as patho-
physiological processes involved in cognitive decline [13,14]
and these same mechanisms have been associated with
depression in CAD [15,16]. Persistent activation of these
pathways appears to precede neurodegeneration and may
contribute to cognitive vulnerability in those with depres-
sion [17]. Platelet-activating factors (PAFs) are a diverse
family of potent alkylacylglycerophosphocholine (lipid)
second messengers. Emerging evidence suggests that
PAF activation is a hallmark of pathological disruption
to membrane-based lipid signaling cascades regulating
inflammatory and apoptotic activity, with various PAFs
demonstrating selective pro- and anti-inflammatory and
neurodegenerative effects [13,18]. Accordingly, PAF activa-
tion has been associated with the presence of CAD and
with inflammation, oxidative stress, and neurodegeneration;
all contemporary mechanisms for depression in CAD [19].
Furthermore, PAFs are increasingly being recognized as key
participants in the neurodegenerative mechanisms associ-
ated with cognitive decline, with indications of variable ef-
fects based on species identity [13,20]. As such, PAFs may
be pertinent biomarkers as well as potential mediators of
cognitive decline in patients with CAD, with particular rele-
vance to those with major depression. Despite these mech-
anistic links, the relationships between PAFs and cognitive
performance in CAD patients with or without depression
have yet to be investigated. Here, we explore a cross-
sectional association between measures of cognitive per-
formance and the plasma abundance of various PAF species
for the first time using a targeted lipidomic approach in pa-
tients with CAD, with and without major depression.
Methods
Ethics statement
This study was approved by the research ethics boards of
Sunnybrook Research Institute, University Health Networkat Toronto Rehabilitation Institute, and Trillium Health
Partners, and was conducted according to the principles
expressed in the Declaration of Helsinki.
Participants
Participants were approached at entry into a cardiac re-
habilitation program at two local centers, the UHN To-
ronto Rehabilitation and Trillium Health Partners cardiac
centers in Toronto, Ontario between September 2010 and
May 2012. Inclusion criteria consisted of the presence of
CAD (myocardial infarction, percutaneous transluminal
coronary angioplasty, coronary artery bypass graft, or
angiographic evidence of at least 50% stenosis in one or
more major coronary arteries) with a minimum of 7 weeks
post-intervention, to ensure CAD stability. Participants
aged 45 to 80, who spoke and understood English, and
provided written and informed consent were considered.
Once included, demographic information, a detailed med-
ical history, and concomitant medications were recorded.
The use of antidepressant medication was permitted on
the condition of dose stability over at least 3 months, to
minimize potential confounding effects (psychological or
physiological) of adjustment to these medications on the
study findings. Participants were excluded if they had a
history of a neurological condition, had a pre-morbid diag-
nosis of any Axis I psychiatric disorder other than depres-
sion, or had a significant acute medical illness (for example
autoimmune condition, uncontrolled diabetes mellitus, or
uncontrolled hypothyroidism).
Schedule of assessments
Performance in specific cognitive domains was assessed
using a multi-domain battery specified by the National In-
stitute for Neurological Disorders and Stroke - Canadian
Stroke Network guidelines for the study of vascular cogni-
tive impairment [21]. This battery included tests of execu-
tive function (the Animal Naming Task, the FAS Controlled
Oral Word Association Test, and the Trail Making Test
Part B), memory (the California Verbal Learning Test II,
immediate and delayed recall, and the Brief Visuospatial
Memory Test, immediate and delayed recall), and attention
and processing speed (the Digit-Symbol Substitution Test
and the Trail Making Test Part A). Scores for each cognitive
test were converted to a z score based on age, sex, educa-
tion, and handedness (where applicable) norms from a rep-
resentative cognitively healthy population for each test and
combined for each domain into a domain composite z score
[21,22]. Global cognition was taken as the composite z
score of all domains.
Depressive symptom severity was measured using the
17-item Hamilton Depression Rating Scale [23] and con-
trolled as a covariate. Patients were also examined for
the presence of a major depressive episode by trained
study personnel using the Structured Clinical Interview
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Diagnostic and Statistical Manual of Mental Disorders
(DSM) IV [24] and those meeting the inclusion criteria
were included in a subgroup analysis, of the PAF-cognition
relationship with CAD patients with major depression.
Sample collection and lipidomic analyses: lipid extraction
and high-performance liquid chromatography electrospray
ionization mass spectrometry
Fasting blood samples were collected at the study visit
and extracted plasma was frozen at −80°C and batched
for analysis. Plasma lipids were extracted using a modi-
fied Bligh and Dyer method [25] adapted, as previously
described, for efficient extraction of alkylacylglyce-
rophosphocholines (PAFs) [20,26,27]. The PAF species
were analyzed using precursor ion scanning with the
diagnosis fragment ion of phosphocholine head group
at m/z 184, as described [20,27]. Identities were pre-
dicted for each m/z value using the online phospholipid
prediction tool VaLID version 1.1 [28], and validated by
analysis of mass spectrometry spectral fragmentation pat-
terns [29] and linear regression models defining retention
times of each PAF subgroup, as described previously [20].
Statistics
The ‘peak area’ of each lipid, representing the area under
the curve in counts per second, was established using
Analyst version 1.4.2 (AB Sciex), normalized to the syn-
thetic internal standard (PAPC(13:0/0:0)) spiked at time of
extraction and multiplied by 1E6 before logarithmic
transformation (base 2). The associations between PAF
abundance and z scores from cognitive performance
tests were investigated using linear regression (Pearson
correlation coefficient (r)) (SPSS statistical software, ver-
sion 13.0, Chicago, IL, USA). Significant associations be-
tween a PAF and global cognitive performance were
then tested in independent covariate-adjusted models,
controlling for the potential influence of age, sex, years
of education, and depressive symptom severity. Participant
characteristics associated with global cognitive perform-
ance in linear regression or group-comparison analyses
were included in independent covariate-adjusted models
as needed. As this study is intended to be hypothesis
generating, the findings were not adjusted for multiple
comparisons.
Results
Ninety-five patients with CAD were assessed for study
eligibility at entry to their cardiac rehabilitation program.
Of those, 57 patients were excluded either because they
did not agree to participate in the research (N = 41) or
because they had begun or changed their dose of anti-
depressant treatment within the previous 3 months (N =
16). Of the remaining 38 eligible patients, 24 agreed toparticipate in this study (participant characteristics are
summarized in Table 1). Those patients included had
HAM-D scores ranging from 3 to 20, and 62.5% of the
patients met DSM-IV criteria for major depression.
Cognitive performance
Performance across all cognitive tests in this sample of
patients was below comparable population norms, with
mean z scores ranging from −0.22 to −0.55 (Table 2).
Similarly, global cognition, as measured by composite z
scores from the tested cognitive domains, was also below
norms, with a mean z score of −0.38 (±0.62). Cognitive
performance was poorer in the major depressed sub-
group (Table 2).
Platelet-activating factors and cognitive performance
Seventy-two phosphocholine second messengers with m/z
between 450 and 600 were detected in patient plasma
samples. Of these, 23 species were identified as PAFs. A
significant association between a greater plasma abun-
dance of the PAF PC(O-18:0/2:0) and poorer global cogni-
tive function (composite z score) was observed in the total
sample of patients (Table 3). That association appeared to
be driven by a significant relationship between a greater
plasma abundance of PC(O-18:0/2:0) and poorer executive
function (r = −0.51, P = 0.01). Trends between a greater
plasma abundance of the PAFs PC(O-16:0/2:0), PC(O-
18:1/2:0), and PC(O-18:6/2:0) and poorer global cognitive
performance were detected (Table 3).
The PAF PC(O-18:0/2:0) remained significantly associ-
ated with poorer global cognitive performance after adjust-
ing for age (βPAF = −0.45, P = 0.03), sex (βPAF = −0.45, P =
0.03), years of education (βPAF = −0.46, P = 0.03), and de-
pressive symptom severity (βPAF = −0.46, P = 0.03) in inde-
pendent models. None of the participant characteristics
was significantly associated with global cognitive perform-
ance (Table 1), thus no characteristics were included as co-
variates in additional models.
Subgroup analysis: patients with CAD with major
depression
Significant associations between a greater plasma abun-
dance of PAFs PC(O-16:0/2:0) and PC(O-18:0/2:0) with
poorer global cognitive performance were observed in a
subgroup of patients with CAD with major depression
(Table 3). Associations with these PAFs and cognition
appeared to be driven mainly by relationships with poorer
executive function. The lyso-PAF PC(O-16:0/0:0) also de-
monstrated a significant negative association with global
cognitive performance in this subgroup (Table 3). Trends
between a greater plasma abundance of PAFs PC(O-
18:1/2:0), PC(O-18:6/2:0), and lyso-PAF PC(O-18:1/0:0)
and poorer global cognitive performance were detected
(Table 3). Conversely, a greater plasma abundance of
Table 1 Participant characteristics




Associations with Global Cognition
(N = 24)
Sociodemographic Value Value (t or r, P value)
Age 60.3 (9.4) 59.6 (9.2) −0.01, 0.98
Male (%) 70.8 73.3 −0.29, 0.78
Living alone (%) 33.3 40.0 −0.52, 0.61
White (%) 70.8 66.7 1.67, 0.20*
Years of education 14.9 (3.1) 15.3 (3.2) 0.10, 0.63
Vascular risk factors
Hypertension (%) 70.8 66.7 −0.21, 0.84
Smoking history (%) 79.2 80.0 0.56, 0.58
Years smoked 27.6 (13.4) 25.3 (13.7) −0.09, 0.70
Diabetic (%) 41.7 40.0 0.31, 0.76
Body mass index 29.8 (5.4) 28.5 (5.3) 0.11, 0.61
Dyslipidemia (%) 79.2 86.7 0.75, 0.46
Number of vascular risk factors 3.6 (1.5) 3.7 (1.5) 0.23, 0.29
VO2 peak (ml/(kg min)) 18.5 (4.7) 19.1 (4.8) 0.17, 0.44
Systolic blood pressure (mm Hg) 121.3 (17.9) 123.9 (16.9) −0.33, 0.11
Diastolic blood pressure (mm Hg) 74.5 (10.7) 77.3 (12.3) −0.12, 0.57
Cardiac history
Percutaneous transluminal coronary angioplasty (%) 20.8 26.7 0.74, 0.58*
Myocardial infarction or ischaemic heart disease (%) 50.0 46.7
Coronary artery bypass graft (%) 29.2 26.7
Median weeks since event 14.0 14.0
First episode of CAD (%) 70.0 60.0 1.56, 0.13
Psychometric
Met criteria for a major depressive episode (%) 62.5 100.0 −0.86, 0.40
History of depression (%) 45.8 53.3 0.59, 0.56
HAM-D score 12.5 (4.8) 14.9 (3.8) −0.20, 0.35
Concomitant medications (%)
Antidepressants 8.3 6.7 0.64, 0.53
Acetylsalicylic acid 75.0 80.0 1.46, 0.16
Platelet inhibitor 66.7 60.0 −1.33, 0.20
Statin 100.0 100.0 -
Anti-inflammatory 4.2 6.7 -
Anti-diabetic agents 37.5 33.3 0.45, 0.66
VO2, volume of oxygen; HAM-D, Hamilton rating scale for depression; t test and Pearson coefficient summarized associations between participant characteristics
and global cognitive performance where appropriate. Data summarized using mean (with standard deviation) unless otherwise stated. *One-way analysis of
variance (ANOVA) (with F value) performed for global cognition across ethnicity and cardiac history groups, respectively.
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cognitive performance in patients with CAD with depres-
sion (Table 3). Sample size precluded covariate-adjusted
models in this subgroup. Neither PC(O-16:0/0:0) (r = 0.17,
P = 0.66), PC(O-16:0/2:0) (r = −0.08, P = 0.83), nor PC(O-
18:0/2:0) (r = −0.17, P = 0.66) were associated with global
cognitive performance in patients with CAD without de-
pression (N = 9). The PAF PC(O-19:5/2:0) (r = −0.73, 0.04)was significantly associated with poorer global cognitive
performance in patients with CAD without depression.
Discussion
These preliminary findings support the hypothesis that the
PAF family of lipid messengers might be associated with
cognitive deficits, with strong associations with executive
dysfunction driving many of the observed relationships.
Table 2 Performance (z scores) on cognitive tasks of the NINDS-CSN cognitive battery
Cognitive task All CAD patients (N = 24) z score
(standard deviation)
Major depressed subgroup (N = 15) z score
(standard deviation)
Executive function −0.35 (0.70) −0.36 (0.76)
Animal Naming Task −0.28 (0.96) −0.31 (0.96)
FAS/COWAT −0.25 (0.92) −0.20 (1.06)
Trail Making Test Part B −0.53 (0.86) −0.58 (0.93)
Attention and processing speed −0.55 (0.78) −0.64 (0.82)
Trail Making Test Part A −0.67 (1.00) −0.81 (1.01)
Digit-Symbol Substitution Test −0.43 (0.76) −0.49 (0.80)
Memory −0.22 (0.95) −0.37 (1.00)
CVLT, immediate recall (Trials 1 to 5) (verbal) −0.51 (1.06) −0.76 (1.01)
CVLT, delayed recall (verbal) −0.17 (0.93) −0.30 (0.96)
BVMT, immediate recall (Trials 1 to 3) (visuospatial) −0.25 (1.39) −0.35 (1.45)
BVMT, delayed recall (visuospatial) −0.02 (1.17) −0.01 (1.19)
Global cognition z score (composite of all sub-domains) −0.38 (0.62) −0.46 (0.59)
BVMT, Brief Visuospatial Memory Test; CVLT, California Verbal Learning Test II; FAS/COWAT, FAS Controlled Word Association Test; NINDS-CSN, National Institute of
Neurological Disorders and Stroke-Canadian Stroke Network.
Mazereeuw et al. Journal of Neuroinflammation 2014, 11:119 Page 5 of 8
http://www.jneuroinflammation.com/content/11/1/119This study also suggests that the relationship between
PAFs and cognitive deficits is strongest in patients with
CAD with major depression, implicating PAFs as poten-
tially highly relevant to cognitive decline in that subgroup.
Deficits in executive function are predictive of acceler-
ated cognitive decline and are often observed in depressed
individuals [31,32]. For example, executive dysfunction is
a hallmark feature of depression associated with vascular
risk factors in later life [33]. As such, executive dysfunc-
tion may be relevant to the increased risk of cognitive de-
cline in those with CAD and, in particular, patients with
CAD with depression. In addition to the risk of cognitive
decline associated with executive dysfunction in later life,
deficits in that domain are associated with poor health
outcomes, such as lower quality of life [34], more frequent
falls [35], reduced adherence to medications or general
health behaviors [36], and in those with depression, re-
duced effectiveness of antidepressant interventions [37],
among many others. Thus, PAFs may be associated with
deficits in this clinically important cognitive domain. Our
results extend the previous literature, as several of the
PAFs found to be associated with cognitive deficits in
this study have established mechanistic relationships with
neurodegenerative processes. For example, previous pre-
clinical work has identified the PAFs PC(O-18:0/2:0) and
PC(O-16:0/2:0) as important pathological species associ-
ated with pro-apoptotic effects in the central nervous sys-
tem [18]. Furthermore, PC(O-16:0/2:0) and its lyso-PAF
precursor, PC(O-16:0/0:0), were found to be elevated in
the temporal cortex of patients with Alzheimer’s disease
post-mortem [20], collectively implicating the PC(O-16:0/
2:0) pathway as a potential marker of neurodegeneration.These results are also consistent with previous literature
demonstrating that different PAF species have unique sig-
naling effects both at the PAF receptor (a major conduit for
PAF signaling) and independently of the PAF receptor [18].
For example, activation of the PAF receptor by PC(O-16:0/
2:0) has been shown to be anti-apoptotic, whereas activa-
tion by PC(O-18:0/2:0) is pro-apoptotic. Additionally, both
PC(O-16:0/2:0) and PC(O-18:0/2:0) have been shown to be
pro-apoptotic through different PAF receptor-independent
pathways [18]. Thus, each PAF identified in the present
study may have a unique signaling potential not only within
the periphery, from where it was sampled, but also in the
central nervous system, and its effects may be variable de-
pending on whether or not it is activating the PAF receptor.
This could explain why the PAF PC(O-19:5/2:0) was associ-
ated with better global cognitive performance in patients
with CAD with depression in this study. For example, it is
possible that PC(O-19:5/2:0) may signal predominantly at
the PAF receptor (or predominantly independently of the
PAF receptor) and that its signaling effect may be anti-
apoptotic. It is also possible that PC(O-19:5/2:0) might be
an anti-inflammatory member of the PAF family whose role
is to counteract the pro-inflammatory effects of the other
PAFs. While caution should be exercised when interpreting
the differential associations between PC(O-19:5/2:0) and
global cognitive performance in patients with and without
depression, this PAF may be of mechanistic interest for fu-
ture study. Unfortunately, the mechanisms by which most
of the PAFs identified by this study signal neurodegene-
rative processes or might be involved in them have yet
to be determined. However, the variable negative, neutral,
and positive associations between PAFs and cognitive
Table 3 Pearson correlations between PAFs and global cognitive performance (composite z score) in patients with CAD
PAF species (m/z
peak and identities)
All patients (N = 24) Major depressed subgroup (N = 15)
Pearson coefficient (r) P Pearson coefficient (r) P
(468.3a) PC(O-12:0/2:0) −0.09 0.67 0.33 0.23
(482.4a) PC(O-13:0/2:0) 0.17 0.44 0.19 0.49
(496.3a) PC(O-14:0/2:0) −0.22 0.31 −0.39 0.16
(494.3a) PC(O-14:1/2:0) −0.22 0.30 0.26 0.36
(510.4d) PC(O-15:0/2:0) 0.20 0.36 −0.12 0.66
(482.4c) PC(O-16:0/0:0) −0.27 0.21 −0.53 0.04*
(524.4a) PC(O-16:0/2:0) −0.35 0.09* −0.52 0.04*
(522.4a) PC(O-16:1/2:0) 0.06 0.78 −0.03 0.92
(520.3a) PC(O-16:2/2:0) −0.08 0.72 −0.03 0.92
(532.3a) PC(O-17:3/2:0) 0.00 0.99 0.12 0.68
(510.4d) PC(O-18:0/0:0) −0.08 0.73 −0.04 0.89
(552.4e) PC(O-18:0/2:0) −0.45 0.03* −0.59 0.02*
(508.6b) PC(O-18:1/0:0) 0.22 0.31 0.45 0.09*
(550.4a) PC(O-18:1/2:0) −0.37 0.08* −0.47 0.08*
(548.4b) PC(O-18:2/2:0) −0.10 0.64 0.14 0.61
(546.3a) PC(O-18:3/2:0) −0.15 0.50 0.19 0.50
(544.4a) PC(O-18:4/2:0) 0.14 0.51 0.16 0.55
(542.3b) PC(O-18:5/2:0) −0.08 0.69 0.28 0.31
(540.4a) PC(O-18:6/2:0) −0.40 0.05* −0.49 0.06*
(556.4d) PC(O-19:5/2:0) 0.12 0.59 0.55 0.03†
(572.3b) PC(O-20:4/2:0) 0.09 0.68 0.32 0.25
(570.3e) PC(O-20:5/2:0) −0.29 0.16 0.03 0.92
(568.4a) PC(O-20:6/2:0) −0.16 0.46 0.14 0.61
Nomenclature adheres to the recent reorganization of ontologies for lipid classes and the curated list of lipid species identified by the Canadian Institutes of
Health Research Training Program in Neurodegenerative Lipidomics (CTPNL) teams [28,30]. PC(O-20:4/2:0), for example, defines a lipid species with a
phosphocholine polar head group (PC), an ether linkage at the sn-1 position (O-) with a chain of 20 carbons and 2 carbons linked by an ester linkage at the sn-2
position, of which the sn-1 chain has four degrees of unsaturation (indicated as: 4) whereas the sn-2 chain is characterized by fully saturated acetyl group (referred
to by: 0). The number preceding species name in brackets refers to m/z of the [M + H]+ ion. Letters distinguish species isobaric with other lipid second messengers
in the curated CTPNL phospholipid list. *Significant negative associations (P ≤ 0.05); †significant positive associations (P ≤ 0.05); CAD, coronary artery disease; PAF,
platelet-activating factor.
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mechanisms of cognitive decline and it may be possible,
through lipidomics, to identify important pathways for fu-
ture investigation.
These preliminary findings are consistent with previ-
ous studies demonstrating an interaction between inflam-
matory messengers and cognitive deficits in populations
without dementia. For example, poorer global cognitive
performance has previously been associated with greater
concentrations of inflammatory cytokines and acute-phase
proteins [3]. Inflammatory markers, such as interleukin-6
and C-reactive protein, have also been associated with
poorer performance on tests of psychomotor speed and
verbal memory in individuals with depression [38-40].
As such, the role of those markers in the relationship
between PAFs and cognitive performance in patients
with CAD with depression should be addressed in fu-
ture studies.This hypothesis-generating study is novel in several
aspects: firstly, these findings are the first indication
that PAF metabolism might be linked to cognitive defi-
cits in CAD patients, with high relevance to patients
with CAD with depression, a group that is at an
elevated risk of accelerated cognitive decline [6]. Sec-
ondly, most of the available literature on PAFs does
not describe PAF species individually, instead classify-
ing PAFs as a type of lipid (that is, a PAF). Only re-
cently has technology permitted a lipidomic approach
to identifying unique PAF species [26,41]. These find-
ings are the first to characterize individual PAF species
in plasma from a clinical sample, adding much needed
context to their potentially unique roles as bioactive
lipid messengers. Finally, the potential of these prelim-
inary findings is enhanced by the lack of confounding
associations between participant characteristics and
cognitive outcomes.
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The interpretation of these findings was limited by the
small sample size and cross-sectional study design.
Moreover, since the study was intended to generate fu-
ture hypotheses, no adjustment was made for multiple
comparisons. As such, it is possible that the associations
(or lack thereof ) between certain PAFs and cognitive
measures might change in a larger sample, revealing
the true associations. As the study population consisted
only of older patients with CAD, we cannot comment
on the potential associations between PAFs and cogni-
tive deficits in those who are medically healthy, those
with depression who do not have CAD, or those youn-
ger than 45. This study also did not address measures of
other cognitive domains (for example, episodic mem-
ory) and therefore these findings cannot be generalized
across all cognitive domains. Finally, these findings are
limited to PAFs derived from alkylacylglycerophosphocho-
lines; however, as mentioned, these are highly abundant
PAFs and are therefore appropriate for this exploratory
pilot study.
Future directions
The PAFs in peripheral blood may indicate a systemic
state of aberrant lipid metabolism, owing to pathophysio-
logical processes of cognitive decline or may signal across
the blood–brain barrier to initiate synthesis of PAFs and
other inflammatory mediators in the central nervous sys-
tem. If our findings are confirmed in a larger sample, PC
(O-18:0/2:0) and PC(O-16:0/2:0) might be particularly
important PAFs to explore in patients with CAD with
depression, considering their consistency of involvement
with global and domain-specific cognitive deficits and
their established mechanistic relevance to neurodegenera-
tion [18,20]. PC(O-18:6/2:0) and PC(O-19:5/2:0) are newly
identified species that represent potential mediators asso-
ciated with depression-related cognitive deficits in CAD.
Should PAFs be confirmed as consistently associated with
cognitive deficits, they might serve as clinically useful bio-
markers of vulnerability to cognitive decline in patients
with CAD. Future studies might clarify the mechanisms
by which these PAFs, and others, might mediate neurode-
generation and cognitive decline in patients with CAD, to
identify mechanistically relevant therapeutic targets.
In the meantime, these preliminary findings support a
role for PAFs as markers of cognitive deficits in CAD
patients and invite investigation of this association in
larger studies.
Conclusions
While preliminary, the findings of this study encourage
further investigation of PAF species, particularly PC(O-
18:0/2:0), as markers of cognitive deficits in CAD patients.
As PAFs are emerging as important lipid mediators at thecore of neurodegenerative pathology, are elevated in
CAD, and are associated with leading mechanisms of
cognitive decline associated with depression, these find-
ings are biologically plausible and potentially clinically
relevant for patients with CAD with depression. Larger
longitudinal studies of PAFs as markers of cognitive de-
cline in CAD patients with and without depression
might clarify their role and clinical utility as biomarkers
or therapeutic targets.
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